Bill Ackman Says Valeant (VRX) Now 'Classic' Pershing Square Investment - CNBC

August 26, 2016 8:15 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Bill Ackman says Valeant Pharma (NYSE: VRX) has made a lot of progress and that a passive position was a "mistake," according to commentary on CNBC today. The investor says Valeant is now a "classic" Pershing Square investment.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hedge Funds, Trader Talk

Related Entities

William Ackman, Pershing Square Capital

Add Your Comment